NeOnc wins Abu Dhabi IND for NEO212 in first international clearance
NeOnc Technologies Holdings (NASDAQ: NTHI) has received Investigational New Drug authorisation from the Department of Health in Abu Dhabi for NEO212, its oral perillyl alcohol-temozolomide conjugate targeting aggressive brain tumours including glioblastoma. The clearance represents the first international regulatory approval for the compound and follows the completion of a Phase 1 dose-escalation study in which 610 mg was established as the recommended Phase 2 dose.
The company is now pursuing clinical development on two regulatory tracks. In the United States, NeOnc is preparing for a Type B End-of-Phase 1 meeting with the FDA to discuss potential Phase 2 pathways and a longer-term registrational strategy. The Abu Dhabi authorisation provides an additional clinical entry point that could generate data relevant to those future regulatory conversations, though the specific trial design and patient population for the UAE programme have not yet been disclosed.
The science and the pipeline
NEO212 is a bioconjugate that pairs the company's proprietary perillyl alcohol compound with temozolomide, the established standard-of-care chemotherapy used in glioblastoma. According to the company's disclosures, preclinical and early-stage findings suggest NEO212 may achieve approximately three times greater brain exposure than temozolomide administered alone, though these figures originate from company materials and have not been independently validated in peer-reviewed data.
The broader thesis underpinning NeOnc's platform centres on blood-brain-barrier penetration. Many oncology agents with solid in-vitro profiles fail in central nervous system indications because they cannot cross into tumour tissue in therapeutically relevant concentrations. NeOnc says its delivery technologies are designed specifically to improve CNS access while reducing systemic toxicity, though clinical proof of that advantage remains pending at scale.
Alongside NEO212, the company's second lead asset, NEO100, is an intranasal formulation of perillyl alcohol intended for direct nose-to-brain delivery. Enrolment has completed in a Phase 2a study in recurrent IDH1-mutant high-grade glioma, with interim and topline data anticipated later in 2026. The company has previously cited a tumour remission rate of approximately 24% in recurrent glioblastoma patients treated with NEO100, though the company itself acknowledges that larger studies will be required to establish clinical significance.
Market context and disclosure
Glioblastoma remains one of the most therapeutically resistant cancers, with median overall survival of roughly 15 months from diagnosis under current standard-of-care regimens. Despite decades of effort, temozolomide and radiotherapy remain the backbone of treatment, and no drug has materially improved survival outcomes since bevacizumab's accelerated approval, which was subsequently withdrawn in the US indication. That persistent unmet need draws continuous investment interest, and a number of companies, including academic spinouts and larger pharmaceutical players, are investigating blood-brain-barrier-targeted delivery strategies alongside NeOnc.
Readers should note that this press release originates from InvestorsTape.com, which discloses it has been compensated for coverage of NeOnc and may receive future compensation. The release also references insider purchasing activity by CEO Amir Heshmatpour, reported at nearly $1 million over the past year, and highlights institutional holders including Bank of America, State Street and Barclays. These details are investor relations framing rather than clinical or regulatory substance; they are noted here for completeness but carry limited editorial weight in assessing the scientific programme.
The next meaningful catalysts for independent assessment are the NEO100 Phase 2a data readouts expected before year-end and the outcome of the FDA Type B meeting on NEO212's Phase 2 pathway.